Maternal Fatigue After Postpartum Anemia Treatment With Intravenous Ferric Carboxymaltose and Oral Iron Therapy
Key facts
- Who runs it
- Pakistan Air Force (PAF) Hospital Islamabad
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 134 people enrolled
- Started
- 20 Apr 2026
- Ended
- 20 Sept 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- INTRAVENOUS FERRIC CARBOXYMALTOSE
- oral iron therapy
- Record updated
- 19 October 2026
Who can take part
- Age
- 18 years to 40 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Women aged 18-45 years
- Postpartum period (within 48 hours)
- Hemoglobin < 10 g/dL
- Singleton delivery
- Willing to participate Exclusion Criteria
- Severe anemia requiring blood transfusion
- Known hemoglobinopathies
- Chronic medical illness (renal, hepatic, cardiac)
- Postpartum sepsis or PPH
- Previous iron therapy in current pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Postpartum Anemia is common after childbirth and may contribute to tiredness and reduced wellbeing in mothers.This randomized controlled trial will compare two treatments for postpartum iron deficiency:intravenous ferric carboxymaltose and oral iron therapy .This study will assess whether intravenous ferric carboxymaltose provides greater improvement in maternal fatigue during the first 6 weeks after childbirth compared to oral iron.Secondary outcomes will be assessment of depressive symptoms and breastfeeding self efficacy .Eligible postpartum women with iron deficiency anemia will be randomly assigned to receive either intravenous ferric carboxymaltose or oral iron therapy and will be followed for six weeks.The study hypothesis is that intravenous ferric carboxymaltose will result in greater improvement in maternalfatigue and may also effect breastfeeding self efficacy .
The 2 groups in the trial
- INTRAVENOUS FERRIC CARBOXYMALTOSE groupTreatment being tested
single dose Intravenous ferric carboxymaltose administered postpartum
Treatment: INTRAVENOUS FERRIC CARBOXYMALTOSE
- oral iron therapy groupExisting treatment, for comparison
oral iron therapy to treat anemia as comparative group
Treatment: oral iron therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Maternal Fatigue After Postpartum Anemia Treatment With Intravenous Ferric Carboxymaltose Versus Oral Iron Therapy
- Record updated
- 19 October 2026